Real-world use of bezlotoxumab to prevent recurrent <i>Clostridioides difficile</i> infections: a single-center experience and meta-analysis
Our retrospective study and meta-analysis demonstrate the real-world efficacy of BEZ in reducing CDI recurrence. The higher recurrence rates in our cohort likely reflect the high-risk nature of the population, including a greater proportion of immunocompromised patients.
Authors
- Darrell S. Pardi (ORCID: https://orcid.org/0000-0003-0420-8784)
- Parul Berry (ORCID: https://orcid.org/0000-0002-0860-4496)
- Raseen Tariq (ORCID: https://orcid.org/0000-0001-7586-6691)
- Kanika Sehgal (ORCID: https://orcid.org/0000-0002-0186-3583)
- Sahil Khanna (ORCID: https://orcid.org/0000-0002-7619-8338)
Institutions
- Yale New Haven Hospital (US)
- Mayo Clinic (US)
- Virginia Commonwealth University (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1177/17562848251346593
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 1.40